Coherus Oncology, Inc. (CHRS) stock
CHRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/3059% below fair value
$0.48−0.03 (-5.42%)
Close on Nov 17, 2026Market cap $73.93MP/E –Yield –
Coherus Oncology pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Coherus Oncology's pe ratio was 1.2× on Jul 31, 2026, against 0.5× a year earlier. Over the last 3 years it ranged from 0.3× to 15.7×, with a median of 4.1×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Jul 31, 2026 | 1.2× | +0.8 |
| 2025 | Dec 31, 2025 | 0.3× | −8.8 |
| 2021 | Apr 30, 2021 | 9.1× | +0.6 |
| 2020 | Dec 31, 2020 | 8.5× | – |
See a number that looks wrong?